TerminatedPhase 1/2

Pioglitazone for Heroin and for Nicotine Dependence

Stopped: The funding period ended.

United States82 participantsStarted 2011-03

Plain-language summary

The goal of the proposed research is to improve the effectiveness of treatments for opioid and for nicotine dependence by testing a novel pharmacological strategy. Specifically, pioglitazone, a peroxisome proliferator-activated gamma receptor (PPARγ) agonist, will be used as an adjunct to agonist-based treatment.

Who can participate

Age range21 Years – 55 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * 21-55 years of age * Physically healthy * Able to perform study procedures Exclusion Criteria: * Pregnancy * Physical dependence on any other drugs besides caffeine, heroin and nicotine

What they're measuring

Drug's Break Point

Timeframe: Following 2 weeks of Pioglitazone (PIO) maintenance.

Trial details

NCT IDNCT01395797

SponsorNew York State Psychiatric Institute

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2014-04

Results submitted2015-08-31

View on ClinicalTrials.gov More Heroin Dependence trials